Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

Robert C. Sterner¹ and Rosalie M. Sterner²*

¹School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States, ²Department of Surgery, Mayo Clinic, Rochester, MN, United States

Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy have limited their use. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) is a potentially life-threatening neurotoxicity that commonly occurs with CAR-T cell therapy. Here we will discuss ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy. This serious, life-threatening side effect needs to be studied to better understand its mechanisms and develop treatments and alternative strategies.

KEYWORDS
chimeric antigen receptor-T cell (CAR-T cell) therapy, ICANS, immune effector cell associated neurotoxicity syndrome (ICANS), CAR-T cell, neurotoxicity, cytokine release syndrome (CRS)

Introduction

Chimeric antigen receptor (CAR)-T cell therapy is a critical staple therapy for certain hematological malignancies (1–6). T cells are the body’s natural defense against abnormal cells including cancer cells. Typically, this requires the T cell receptor to recognize the peptide antigen of interest in the context of the appropriate major histocompatibility complex. CARs are synthetically engineered receptors expressed in T cells that allow the T cells to recognize independent antigen on the surface of cells. Thus, CAR T cells can recognize antigen and become activated independent of MHC, resulting in robust activation and tumor destruction (7). Since 2017, multiple CAR-T cells have been approved by the US Food and Drug
suggesting a T cell unique pathophysiology (16). Here we will discuss ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy (2, 17).

CAR-T cell associated toxicities

While CAR-T cell therapies have had impressive success, life threatening toxicities have prevented them from becoming a first line therapy. CAR-T cells have caused significant morbidity and mortality via these three main toxicity syndromes (8, 9, 18, 19). The three main types of toxicities include: (a) cytokine release syndrome (CRS), which is caused by massive cytokine levels and T cell expansion; (b) hemophagocytic lymphohistiocytosis and/or macrophage activation syndrome (HLH/MAS), which is characterized as a hyperinflammatory state of CRS plus elevated serum ferritin and hemophagocytosis, renal failure, elevated liver enzymes, splenomegaly, pulmonary edema, and/or absence of NK cell activity; and (c) immune effector cell-associated neurotoxicity syndrome (ICANS), which is associated with increased cerebrospinal fluid cytokine levels and disruption of the blood-brain barrier (20). In patients treated with CAR-T cell therapy 20-70% develop ICANSs (3–5, 10–14). All FDA approved CAR-T cell products have had incidents of ICANS, thus ICANS is not a phenomena specific to anti-CD19 antigenicity (3–6). Interestingly, CD22 targeting CAR-T cells have not been associated with worse ICANS even though CD22 is expressed by human microglia (21–23).

Grading and treatment of ICANS

Patients at greater risk for ICANS include those with younger age, pre-existing neurological/medical conditions, high tumor burden, high intensity lymphodepleting therapy, cytopenias, and early/severe CRS (14, 20, 24–28). Clinically, ICANS can present from confusion, headache, attention deficits, word finding difficulties, focal neurological deficits, or encephalopathy to life threatening cerebral edema, transient coma, or seizures (29). Classically, ICANS develops in 3 to 10 days following CAR-T cells being given (14, 20, 27). Frequently, ICANS occurs 2 to 4 days after onset of CRS, although ICANS is not required to occur in the context of CRS (14, 20, 27). Symptoms typically begin as inattention and language deficits and deterioration can rapidly progress over the course of hours to days. Usually, symptoms resolve within 7 to 10 days with appropriate treatment, but some patients will require prolonged ICU stays, and fatalities have been attributed to significant cerebral edema (14, 24, 30–33). Patients exhibit increased lactate dehydrogenase, thrombocytopenia, increased inflammatory markers, and increased cytokine levels (14, 25). Electroencephalography is often abnormal with frontal or diffuse theta-delta slowing being the most commonly observed pattern (34). In severe ICANS with increased ICP, white matter changes and sulcal effacement due to diffuse cerebral edema can be observed on imaging studies (30, 35, 36).

The American Society for Transplantation and Cellular Therapy (ASTCT) has worked to integrate various grading scales of ICANS (29, 33, 37). Grade 1 patients (mild) exhibit inattentiveness, mild disorientation, as well as mild expressive and/or receptive language dysfunction (patients can still communicate). Grade 2 patients (moderate) have moderately impaired levels of consciousness but respond to voice. Grade 3/4 patients (severe) have significant language dysfunction, respond only to tactile or noxious stimulation, and may have seizures. While the diagnose of ICANS can consistently be diagnosed using a variety of grading systems (91% of the time in one grading study), there is significant variable in grade of ICANS based on the grading scale used with only 54% of ICANS patients remaining in the same grade when using different grading scales, thus, consistent use of grading scales is critical for future trials (38). Severe ICANS (grade 3 or above) ranges from approximately 10-28% in pivotal trials in the most classically studied LBCL anti-CD19 CAR-T cells studies (39).

Treatment for ICANS remains challenging, focusing mainly on supportive care and close monitoring. Steroids are the mainstay of management and are typically started with grades 2 or greater ICANS. Unfortunately, the optimal timing, dose, and duration of corticosteroids remains unclear (14, 40, 41). Furthermore, there are no targeted or prophylactic therapies to prevent any CAR-T associated toxicities, in part due to limited knowledge of
ICANS pathophysiology. IL-6 blockade with tocilizumab, while an excellent treatment for CRS, has demonstrated limited utility in ICANS to date (3, 8, 9, 21, 22). Alternative cytokine-directed therapies remain under active investigation.

**Mechanisms of ICANS and possible solutions**

The mechanisms behind ICANS are not well understood. Patients with severe ICANS can develop endothelial activation, disseminated intravascular coagulation, capillary leak, and blood-brain barrier permeability including increased protein and T cells in the CSF with this permeability leaving the CSF open to cytokine infiltration (23, 42). Astrocyte injury has been observed through elevated S100b and glial fibrillary acidic protein in the CSF (43, 44). The CSF has shown increased white blood cell counts, proteins, IFNγ, IL-6, IL-10, and granzyme B with serum increases in IFNγ, IL-10, granzyme B, GM-CSF, MIP-1α, and TNF (43, 44). High grade ICANS has been associated with serum elevations of GM-CSF, IL-2, and ferritin, with GM-CSF being the most associated with high grade ICANS (3, 44). There has also been a significant increase of CD14+ cells observed in patients with high grade ICANS (44, 45). Thus, it appears that a compilation of cytokines, myeloid cells, T cells, and disruption of the blood brain barrier play a role in ICANS (2, 44). A summary of ICANS markers in human patients is provided in Table 1.

| Type of Marker | Markers |
|----------------|---------|
| Serum Markers  | Lactate dehydrogenase, Thrombocytopenia, Ferritin, IFNγ, IL-6, IL-10, Granzyme B, GM-CSF, MIP-1α, TNF |
| CSF/Blood Brain Barrier Disruption Markers | White blood cells, T cells, CD14+ cells, Astrocyte injury (S100b and glial fibrillary acidic protein), Increased protein permeability, IFNγ, IL-6, IL-10, Granzyme B |
| Circulatory Changes | Endothelial activation markers, DIC markers |
| EEG Changes    | Frontal or diffuse theta-delta slowing |
| Imaging Changes| White matter changes, Sulcal effacement |

One of the difficulties of studying ICANS is the limited number of animal models. In a rhesus macaque model of ICANS using CD-20-specific CAR-T cells, CRS and neurotoxicity were induced in 7-8 days (44, 46). IL6, IL8, IL1RA, MIG, and I-TAC were increased in the serum, and IL6, IL2, GM-CSF, and VEGF were disproportionately increased in the CSF (44, 46). T cells and CAR-T cells were found in the brain (44, 46). In a humanized ALL-GM leukemic cell line mouse model, mice developed a CRS like illness at around one week that lasted 2-3 weeks and increased IL-6 (44, 47). In mice that developed the CRS like illness, regardless of treatment status with the IL-6 receptor blocker tocilizumab or vehicle control, a lethal neurological syndrome developed at 30 days (44, 47). Interestingly, those mice treated with the IL-1R blocker anakinra did not develop this neurological syndrome (44, 47). The neurological syndrome was characterized by meningeal thickening without CNS infiltration of leukemic cells but infiltration of macrophages into the subarachnoid space (44, 47). In another model, a primary patient derived xenograft model of ALL was used to generate a neurotoxicity model that showed upregulation of genes responsible for controlling the T-cell receptor, cytokine receptors, T-cell immune activation, T-cell trafficking, and T-cell and myeloid cell differentiation (44, 48). Five days after anti-CD19 CAR-T cell treatment, mice exhibited T1 enhancement on MRI, which is a marker of increased blood-brain barrier permeability as well as possible edema (44, 48). These mice also exhibited neurological symptoms (44, 48). Interestingly, mice treated with GM-CSF neutralizing antibodies exhibited reduced blood-brain barrier permeability, similar to controls that did not receive anti-CD19 CAR-T cells (44, 48). T cells and macrophages were observed in the brains of mice with neurotoxicity and a decrease in raw averages was observed in mice treated with GM-CSF neutralizing antibodies (although it did not reach statistical significance) (44, 48). Thus, the timing, MRI findings, symptoms, cytokine profile, and cellular infiltration was similar in this model to what is observed in humans, and the study showed GM-CSF with neutralizing antibodies reduced neurotoxicity (44, 48). Furthermore, a CRISPR-Cas9 knockout of GM-CSF CAR-T cell was developed in these studies, which may also reduce neurotoxicity (44, 48, 49). Thus, selective control of specific cytokines may aid in the control of ICANS.

**TABLE 1 Markers of ICANS in Human Patients.**

*Via in vivo studies, MRI findings, and increased prevalence of string capillaries (50). Histology showed brain hemorrhage, diffuse extravascular immunoglobulin deposition, loss of capillary pericyte coverage, and increased prevalence of string capillaries (50).*
CAR structure and manipulation to reduce toxicities

CARs are synthetically engineered receptors that are composed of an antigen-binding domain, hinge region, transmembrane domain, and at least one intracellular signaling domain. For CAR-T cells to work effectively, the antigen binding domain must engage with the target antigen to achieve activation and cytokine production but without reaching toxic levels. The antigen expressed on malignant cells, tumor burden, antigen binding domain’s affinity to its target epitope, and the CAR’s costimulatory elements all contribute to the level of CAR activation and risk of toxicity (51, 52). These elements can be modulated through altering CAR structure in order to tune activation level and minimize the risk of toxicity.

The antigen binding domain is the portion of the CAR that confers target antigen specificity. Classically, the antigen binding domains are made from the variable heavy (VH) and light (VL) chains of monoclonal antibodies, and are connected with a linker to produce the single-chain variable fragment (scFv), which typically target extracellular surface cancer antigens resulting in major histocompatibility complex (MHC)-independent T cell activation (42, 53). The scFV also determines the affinity and specificity of the CAR for its target epitope, which ideally should be high enough to recognize antigens on tumor cells, induce CAR signaling, and activate T cells but not so high as to result in activation induced death of the CAR-T cell or trigger toxicities (54–56). Theoretically, reducing the affinity of the antigen binding domain will require the higher antigen levels in order for activation to occur. Thus, a requirement for higher levels of antigen could help reduce the targeting of healthy tissue and lessen undesired activation. Antigen binding domains with micromolar affinity have been shown to be more selective for tumors with higher antigen levels compared to those with lower nanomolar/sub-nanomolar affinity (55). Another contributing factor to toxicity includes the immunogenicity of the of the antibody fragments, which can be reduced by using human or humanized antibody fragments instead of murine fragments (57).

The hinge or spacer region is the extracellular structural region that extends the binding units from the transmembrane domain. The hinge region allows flexibility to overcome steric hindrance and provides length to let the antigen-binding domain access the targeted epitope. The hinge region can affect flexibility, CAR expression, signaling, epitope recognition, strength of activation outputs, epitope recognition, and synapse formation (58–60).

The transmembrane domain anchors the CAR to the cell membrane. Importantly, the transmembrane domain may also be relevant for CAR-T cell functions such as CAR expression level, stability, dimerization with endogenous signaling molecules, and appears to play an active role in signaling or synapse formation (61–63). CAR transmembrane domains are typically derived from CD3ζ, CD4, CD8α, or CD28. Together, the impact of the transmembrane domain and the hinge region also appear to influence CAR-T cell cytokine production and activation induced cell death (AICD) (64). In addition, the hinge and transmembrane domains can play a role in modulating cytokine secretion. Modifying the CD8-α derived hinge and transmembrane sequences of an anti-CD19 CAR resulted in reduced proliferation and cytokine release (65). In a phase I study, 6/11 patients (54.5%) had complete remission of their B cell lymphoma and there were no CRS or ICANS events greater than grade 1 (65). The hinge and transmembrane domains may also confer immunogenicity that can contribute to toxicity (57, 66). Modification of the CAR hinge and transmembrane domains has been shown to reduce immunogenicity and enhance persistence (57, 66).

Much attention has been paid to CAR co-stimulation with the goal of generating CAR constructs with the optimal endodomain. First generation CARs contained a CD3ζ or FcRγ signaling domain, but this first generation did not generate robust durability and persistence (67–70). IL-2 production and proliferation was improved by adding a co-stimulatory domain (71). In second generation CARs, one co-stimulatory domain is placed in series with the CD3ζ intracellular signaling domain (71, 72). Among co-stimulatory domains used in second generation CARs, CD28 and 4-1BB (CD137) are the two most common and both are associated with high patient response rates (71, 72). The co-stimulatory domains differ in their functional and metabolic profiles. CARs with CD28 domains differentiate into effector memory T cells and mainly use aerobic glycolysis. CARs with the 4-1BB domain differentiate into central memory T cells and have increased mitochondrial biogenesis and oxidative metabolism (73). The 4-1BB co-stimulatory domain has been associated with lower toxicities, longer T cell endurance, and lower T cell expansion. On the other hand, the CD28 domain are linked with more rapid onset and exhaustion. Thus, the 4-1BB domain may produce less toxicity in cases of high antigen burden whereas the CD28 domain may be needed to achieve activation in low antigen density situations (74). Clinically, second generation CAR-T cells have produced strong therapeutic responses in several hematological malignancies (52). It has been hypothesized that co-stimulation through only one domain produces incomplete
activation, resulting in the production of third generation CARs, which incorporate two costimulatory domains in series with CD3ζ (75). Preclinical studies of third generation CARs have produced mixed results (76–78).

“Off switches” or suicide genes are another strategy to stop toxicity. A secondary inducing agent can be used to selectively inhibit CAR-T cells during toxicity (79). An example of this strategy is engineering CARs to express CD20 to allow for their depletion with rituximab (80–82). A similar strategy is suggested for Cetuximab therapy for a non-signaling truncated version of EGFR to deplete CAR-T cells (83). Antibody-mediated depletion can be slow in patients who need immediate intervention during toxicities, which potentially limits this strategy. In light of this, inducible cas9 switches have been attempted, which have been shown to successfully eliminate greater than 90% of CAR-T cells in 30 minutes (84). Protease based small molecule-assisted shutoff CAR-T cells (SMASH-CARs) or switch-off (SWIFF-CARs) have also been developed (85). The main problem with these strategies, however, are that they quickly halt therapy, which could be a problem in rapidly progressing disease. Thus, suicide gene engagement could serve as a last resort for safety. A summary of basic CAR-T cell structure and possible edits to alter efficacy is provided in Figure 1.

Discussion

Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) is a potentially life-threatening neurotoxicity that commonly occurs with CAR-T cell therapy. Clinically, ICANS can present with clinical symptoms ranging from confusion, headache, attention deficits, word finding difficulties, focal neurologic deficits or encephalopathy, to life threatening cerebral edema, transient coma, or seizures (29). Supportive care and corticosteroids are the mainstays of treatment, but the optimal timing, dose, and duration of corticosteroids has not been determined (14, 40, 41). Although the precise mechanisms of ICANS are not known, disruption of the blood-brain barrier, cytokines, myeloid cells, and T cells have all been suggested to play a role. In the future, blocking some of these cytokines networks or designing CAR-T cells structurally to be less toxic are strategies to potentially one day overcome ICANS. In this review we discussed ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy. This serious, life-threatening side effect
requires further investigation in the future in order to better understand its mechanisms and develop treatments and alternative strategies.

**Author contributions**

RCS and RMS designed, wrote, edited, and approved the final version of the manuscript. RMS supervised the study. All authors contributed to the article and approved the submitted version.

**Funding**

This work was supported through Regenerative Medicine Minnesota RMM 012819 EPC 003 (RMS). RCS was supported by 1 F30 MH124824-01.

**References**

1. June CH, O'Connor RS, Kwasnekar OU, Ghassemi S, Mdlone MC. CAR T cell immunotherapy for human cancer. *Sci (New York NY)*. (2018) 359(6382):1361–5. doi: 10.1126/science.aar6711

2. Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. *Blood Cancer J* (2021) 11(4):69. doi: 10.1038/s41408-021-00459-7

3. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Milford DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *New Engl J Med* (2017) 377(26):2531–44. doi: 10.1056/NEJMoa1707447

4. Schuster SJ, Bishop MR, Tam CS, Walter EK, Berchmann P, McGuirk JP, et al. Tasigengcleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *New Engl J Med* (2019) 380(1):45–56. doi: 10.1056/NEJMoa1804980

5. Abramson JS, Palomba ML, Gordon LT, Lunning MA, Wang M, Armasen J, et al. Lisoctengacne maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. *Lancet (London England)*. (2020) 396(10254):839–52. doi: 10.1016/S0140-6736(20)33166-0

6. Munshi NC, Anderson LDR, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vilocucel in relapsed or refractory multiple myeloma. *New Engl J Med* (2021) 384(8):705–16. doi: 10.1056/NEJMoa2024850

7. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. *Cancer discovery*. (2013) 3(4):388–98. doi: 10.1158/2159-8290.CD-12-0548

8. Maude SL, Laetsch MW, Buschner J, Rives S, Buyer M, Bittencourt H, et al. Tasigengcleucel in children and young adults with b-cell lymphoblastic leukemia. *New Engl J Med* (2018) 378(5):439–48. doi: 10.1056/NEJMoa1709866

9. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory b-cell lymphomas. *New Engl J Med* (2017) 377(26):2545–54. doi: 10.1056/NEJMoa1708566

10. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. *Hematol Am Soc Hematol Educ Program*. (2016) 2016(1):567–72. doi: 10.1182/ashbt2016.1.567

11. Wang ML, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results phase 2 ZUMA-2 study (2019) 124:754.

12. Schuster SJ. Tasigengcleucel in diffuse large B-cell lymphoma. *Reply. New Engl J Med* (2019) 380(16):1586. doi: 10.1056/NEJMjs1901464

13. Holtzman NG, Xie H, Bentzen S, Kesarvi V, Bubhara A, El Chaer F, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. *Neuro-oncology*. (2021) 23(1):112–21. doi: 10.1093/neuonc/noaa183

14. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany JC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. *Blood* (2019) 133(20):2212–21. doi: 10.1182/blood-2018-12-933396

15. Burton LB, Eshkai M, Guadin AC, Reynolds KL. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. *Neuro-oncol Adv* (2021) 3(Suppl 3):v108–v20. doi: 10.1093/neuonj/vdab107

16. Lu H, Zhao X, Li Z, Hu Y, Wang H. From car-t cells to car-nk cells: a developing immunotherapy method for hematological malignancies. *Front Oncol* (2021) 11:720501. doi: 10.3389/fonc.2021.720501

17. Sterner RM, Hedén KE, Hayden RE, Nowakowski GS, Wyles SP, Greenberg, Worshek AI, et al. A graduate-level interdisciplinary curriculum in CAR-T cell therapy. *Mayo Clinic Proc Innovations Qual outcomes*. (2020) 8(2):203–10. doi: 10.1016/j.mayocp.2019.12.006

18. RCDI. *FDA Approves tisagenlecleucel for b-cell ALL and tisochizumab for cytokine release syndrome. FDA: Maryland* (2019).

19. Park JH, Reeve I, Gonen M, Wang X, Smichčál R, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *New Engl J Med* (2018) 378(5):449–59. doi: 10.1056/NEJMoa1709919

20. Santomasso BD, Park JH, Salloum D, Riveiere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with car-t cell therapy in patients with b-cell acute lymphoblastic leukemia. *Cancer discovery*. (2018) 8(8):958–71. doi: 10.1158/2159-8290.CD-17-1319

21. Davila ML, Riveiere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in b cell acute lymphoblastic leukemia. *Sci Trans Med* (2014) 6(224):224ra25. doi: 10.1126/scitranslmed.3008226

22. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. (2014) 124(2):188–95. doi: 10.1182/blood-2014-05-552729

23. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. *Nat Rev Immunol* (2022) 22(2):85–96. doi: 10.1038/s41577-021-00547-6

24. Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. *BRAIN: Neurology*. (2019) 142(5):1334–48. doi: 10.1093/brain/aws055

25. Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. *JAMA Neurology*. (2020) 77(12):1536–42. doi: 10.1001/jamaneuro.2020.2703

**Conflict of interest**

RMS is an inventor on patents related to CAR-T cell therapy licensed to Humanigen through Mayo Clinic.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large b-cell lymphoma. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity associated with immune effector cells. Antigen receptor T-cell immunotherapy. RM, et al. Neuropathology of a case with fatal CAR T-Cell-Associated cerebral injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Inflammation of tumor and normal tissue in vivo. Vickers AJ, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for CAR-T cell function in xenografts. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadda RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. (2019) 133(7):697–709. doi: 10.1182/blood-2018-10-881722
Sterner RM, Cox MJ, Sakemura R, Rendesian SS. Using CRS/FI/Car to knock out GM-CSF in CAR-T cells. J visualized experiments: JoVE (2019) 149: e9629. doi: 10.3791/9629
Faulhaber LD, Phuong AQ, Hartsuyker KJ, Cho Y, Mandy KK, Harper SD, et al. Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. Brain Commun (2022) 4(1): fcab309. doi:10.1093/braincomms/fcab309
Milone MC, Bhoi VG. The pharmacology of T cell therapies. Mol Ther Methods Clin Dev (2018) 8:210–21. doi: 10.1038/mt.2018.010
van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discovery. (2015) 14(7):499–509. doi: 10.1038/nrd4597
Saqif S, Purdon TJ, Danianan AF, Koneru M, Dao T, Liu C, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracerebral wilms tumor 1 antigen. Leukemia. (2017) 31(8):1788–97. doi: 10.1038/leu.2016.373
lymphoma using genetically modified autologous CD20-specific T cells. *Blood.* (2008) 112(6):2261–71. doi: 10.1182/blood-2007-12-128843

70. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. *J immuno therapy cancer.* (2017) 5:22. doi: 10.1186/s40425-017-0222-9

71. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. *Nat Biotechnol* (2002) 20(1):70–5. doi: 10.1038/nbt107-2

72. Imai C, Mi hara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia.* (2004) 18(4):675–84. doi: 10.1038/sj.leu.2403302

73. Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. *Immunity.* (2016) 44(2):380–90. doi: 10.1016/j.immuni.2016.01.021

74. Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. *Sci signaling* (2018) 11(544):eaat6753. doi: 10.1126/scisignal.aat6753

75. Pulé MA, Straathof KC, Dotti G, Heshup HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Mol therapy: J Am Soc Gene Ther* (2005) 12(5):833–41. doi: 10.1016/j.ymthe.2005.04.016

76. Zhong XS, Matsushita M, Plotkin J, Rivière I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-xL activation and CD8+ T-cell-mediated tumor eradication. *Mol therapy: J Am Soc Gene Ther* (2010) 18(2):415–20. doi: 10.1038/mt.2009.210

77. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Hum Gene Ther* (2014) 25(12):1003–12. doi: 10.1089/hum.2013.209

78. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Mol therapy: J Am Soc Gene Ther* (2009) 17(8):1453–64. doi: 10.1038/mt.2009.83

79. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. *Front Pharmacol* (2014) 5:254. doi: 10.3389/fphar.2014.00254

80. Tasian SK, Kerdierian SS, Shen F, Ruella M, Shestova O, Koulowski M, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood.* (2017) 129(17):2395–407. doi: 10.1182/blood-2016-08-736041

81. Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. *Blood.* (2014) 124(8):1277–87. doi: 10.1182/blood-2014-01-454020

82. Alton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, et al. A versatile safeguard for chimeric antigen receptor T-cell immunotherapies. *Sci Rep* (2018) 8(1):8972. doi: 10.1038/s41598-018-27264-w

83. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. *Blood.* (2011) 118(5):1255–63. doi: 10.1182/blood-2011-02-337360

84. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *New Engl J Med* (2011) 365(18):1673–83. doi: 10.1056/NEJMoai1106152

85. Juillerat A, Tkach D, Russe BW, Tembourni S, Alton J, Ducler E, et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. *BMC Biotechnol* (2019) 19(1):44. doi: 10.1186/s12896-019-0537-3